MICROVUE^™ FGF-23 ELISA (Intact)

The MICROVUE Human FGF-23 (Intact) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media.

Product Specifications

Citations	12
Specimen	Plasma or Cell Culture Supernatent, 100 µL
LLOQ	0.0015 ng/mL
ULOQ	N/A
Assay Time	3.5 hours
Cross Reactivity	None

Technical Documents

Ordering Information

For Research Use Only. Not for use in diagnostic procedures.

Catalog Number	60-6600
Catalog Number (CE)
Size	96 wells/test
Price (USD)	$900.00
Price (EURO)	800,00 €

Contact us

US Phone	+1 (858) 552 1100
EU Phone	+353 (91) 412 474
US Email	customerservice@quidelortho.com
EU Email	EMEACustomerService@quidelortho.com

Specifications
Citations
Certificate of Analysis

Specifications

Description	The MICROVUE Human FGF-23 (Intact) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media.
Size	96 wells/test
Form	96 well plate with 12 eight-well strips in a resealable foil pouch
Specimen	Plasma or Cell Culture Supernatent, 100 µL
Limit of Detection (LOD)	0.0015 ng/mL
Lower Limit of Quantitation (LLOQ)	0.0015 ng/mL
Upper Limit of Quantitation (ULOQ)	N/A
Intra Assay	2.0 - 4.1%
Inter Assay	3.5 - 9.1%
Standards	6
Controls	2
Sample Values	N/A
Assay Time	3.5 hours
Cross Reactivity	None
Storage	Store unopened kit between 2°C to 8°C. Refer to manual for storing individual components
Background	Fibroblast growth factor 23 (FGF-23), which is produced by bone cells, is a novel member of a large family of related proteins. Its gene encodes a 251 amino acid protein. The amino-terminal portion of FGF-23 (aa 1-24) is hydrophobic and is likely to serve as a signal peptide allowing its secretion into the blood circulation. Its carboxyl-terminal portion (aa 180-251) shares only limited amino acid homology with other members of the FGF family of proteins.

Citations

Title	Year	Applications	Sample Species	Sample	Sample Details
Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis	2009	ELISA	Human	Plasma
Evaluation of a method for fibroblast growth factor-23: a novel biomarker of adverse outcomes in patients with renal disease	2010	ELISA	Human	Plasma
Evaluation of a method for fibroblast growth factor-23: a novel biomarker of adverse outcomes in patients with renal disease	2010	ELISA	Human	Serum
The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease	2010	ELISA	Human	Plasma
Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients	2012	ELISA	Human	Serum	Chronic Kidney Disease
Biological variability of plasma intact and C-terminal FGF23 measurements	2012	ELISA	Human	Plasma
The use of fibroblast growth factor 23 testing in patients with kidney disease	2014	ELISA	Human	Plasma
Correlates and Longitudinal Renal and Cardiovascular Implications of FGF23 Levels in HIV-Positive Individuals	2016	ELISA	Human	Plasma	HIV
C-Terminal to Intact Fibroblast Growth Factor 23 Ratio in Relation to Estimated Glomerular Filtration Rate in Elderly Population	2016	ELISA	Human	Plasma
Dietary phosphate supplement does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia	2016	ELISA	Human	Plasma
Under-recognized Hypoparathyroidism in Thalassemia	2018	ELISA	Human	Plasma	Hypoparathyroidism
Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial	2020	ELISA	Human	Plasma	Chronic Kidney Disease
Both enantiomers of β-aminoisobutyric acid BAIBA regulate Fgf23 via MRGPRD receptor by activating distinct signaling pathways in osteocytes	2024	ELISA	Human	Plasma
Role of fibroblast growth factor-23 as an early marker of metabolic bone disease of prematurity	2024	ELISA	Human	Plasma	Metabolic bone disease of prematurity
Prostaglandin E(2) signaling through prostaglandin E receptor subtype 2 and Nurr1 induces fibroblast growth factor 23 production	2024	ELISA	Human	Serum
Targeted Deletion of Fibroblast Growth Factor 23 Rescues Metabolic Dysregulation of Diet-induced Obesity in Female Mice	2024	ELISA	Mouse	Serum	Obesity
Targeted Deletion of Fibroblast Growth Factor 23 Rescues Metabolic Dysregulation of Diet-induced Obesity in Female Mice	2024	ELISA	Mouse	Serum	Obesity
Controlled dietary phosphate loading in healthy young men elevates plasma phosphate and FGF23 levels	2024	ELISA	Human	Plasma
C-terminal FGF-23 production coupling with aldosterone via FAM20C and predicting cardiovascular events in primary aldosteronism	2025	ELISA	Human	Plasma	Cardiac dysfunction
Factors associated with phosphate homeostasis in children with beta-thalassemia major: An analytical cross sectional study from Pakistan	2025	ELISA	Human	Plasma	Beta-thalassemia
Neurofibromatosis type I (NF1) and bone involvement in a pediatric setting: insights from FGF23 levels	2025	ELISA	Human	Plasma	Neurofibromatosis
The vitamin D(3) hormone, 1,25(OH)(2)D(3), regulates fibroblast growth factor 23 (FGF23) production in human skin cells	2025	ELISA	Cell Culture		Neurofibromatosis
The Roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage	2025	ELISA	Human	Plasma
Changes in local mineral homeostasis facilitate the formation of benign and malignant testicular microcalcifications	2025	ELISA	Human	Testicular tissue
Increased Plasma Fibroblast Growth Factor 23 and In-hospital Acute Kidney Injury after Cardiac Surgery	2025	ELISA	Human	Plasma	Acute kidney injury
Correlation Between Fibroblast Growth Factor 23 and Biochemical Parameters in Hemodialysis Patients With End-Stage Renal Disease	2025	ELISA	Human	Serum	Chronic Kidney Disease
Serum fibroblast growth factor 23 and kidney injury molecule-1 in the prediction of acute kidney injury in critically-ill patients	2025	ELISA	Human	Serum	Acute kidney injury
Baseline intact fibroblast growth factor 23 and risk of kidney disease progression in the Indian Chronic Kidney Disease cohort: a prospective multicenter study	2025	ELISA	Human	Plasma	Chronic kidney disease
Age- and sex-specific reference values for phosphate homeostasis parameters-fibroblast growth factor 23 and soluble Klotho	2026	ELISA	Human	Plasma
Fibroblast growth factor-23 as an early biomarker of ischemic acute kidney injury after partial nephrectomy: prospective observational study	2026	ELISA	Human	Plasma	Acute kidney injury

Certificate of Analysis

Showing results for

No results found for

MICROVUE™ FGF-23 ELISA (Intact)

The MICROVUE Human FGF-23 (Intact) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media.

Product Specifications

Ordering Information

Contact us

Specifications

Citations

Certificate of Analysis

MICROVUE^™ FGF-23 ELISA (Intact)